Oral Medications for Ocular Conditions

Systemic Treatments for Common Ocular Conditions


Ocular Oral Medication Overview

When Oral Therapy Is Indicated

Systemic medications become essential when topical therapy cannot reach target tissues, when adnexal or orbital structures are involved, or when inflammation and infection extend beyond the ocular surface. Oral agents provide reliable tissue penetration and sustained serum levels that topical drops cannot match. They are critical for preseptal cellulitis, dacryocystitis, severe rosacea related blepharitis, herpes zoster ophthalmicus, and acute intraocular pressure spikes. Selecting the correct drug and dose early in the disease course improves outcomes and can prevent vision threatening complications.

Commonly Used Systemic Antibiotics

Doxycycline and azithromycin are frequently used for meibomian gland dysfunction, rosacea associated blepharitis, and chronic lid disease due to their anti inflammatory effects and meibum altering properties. Broad spectrum oral antibiotics are indicated for cellulitis involving the lids or orbit and should be chosen based on likely organisms and local resistance trends. Clinicians must account for gastrointestinal intolerance, photosensitivity with tetracyclines, and drug interactions such as reduced absorption with calcium or iron containing supplements. Pediatric dosing and pregnancy safety categories require special attention when prescribing in these populations.

Systemic Antivirals for Herpetic Eye Disease

Acyclovir, valacyclovir, and famciclovir are mainstays in treating herpes simplex keratitis, herpes zoster ophthalmicus, and recurrent epithelial disease. Early initiation within seventy two hours of rash onset in zoster reduces acute pain and lowers the risk of post herpetic neuralgia. Long term low dose prophylaxis can reduce recurrence in patients with frequent HSV flares or after corneal transplantation. Renal function guides dosing and interval adjustments, and adequate hydration is important to minimize crystalluria and neurotoxicity risks.

Oral Carbonic Anhydrase Inhibitors in Glaucoma

Acetazolamide and methazolamide rapidly lower intraocular pressure by reducing aqueous production and are invaluable in acute angle closure, post laser spikes, and situations where multiple topical agents are insufficient. Systemic side effects include paresthesias, diuresis, metabolic acidosis, kidney stones, and rare hematologic reactions, so baseline medical history and lab monitoring are important for extended courses. Caution is warranted in sulfa allergic patients, those with sickle cell disease, hepatic dysfunction, or severe renal impairment. Short term use with clear stop dates minimizes risk while bridging patients to laser or surgical interventions.

Patient Selection, Contraindications, and Counseling

Evaluate age, pregnancy status, systemic comorbidities, current medication lists, and insurance coverage before prescribing. Educate patients about expected side effects such as GI upset, metallic taste, tingling of fingers or toes, and photosensitivity, and instruct them to report rash, shortness of breath, or severe fatigue promptly. Clarify dosing schedules, food interactions, and the importance of completing antibiotic courses. Document counseling points and provide written instructions to improve adherence and reduce phone calls for clarification.

Follow Up, Documentation, and Stewardship

Schedule follow up to verify clinical response, adjust doses, and discontinue therapy when goals are met. Track lab values if therapy extends beyond a few days for CAIs or in medically complex patients on antivirals. Practice antimicrobial and antiviral stewardship by narrowing or stopping agents once cultures or clinical improvement allow. Maintain updated dosing tables, contraindication lists, and cost comparisons so modifications can be made efficiently during subsequent visits.

Opthalmic Oral Medications


Opthalmic Oral Medications. Columns: Brand plus available fields.
BrandGenericDosingAmountAgesPregnancyMechanism
GenericPO
amoxicillin500mg po bid-tid x10d250/500/875mg>3 monthsBpenicillin
GenericPO
amoxicillinclavulanate250-500mg po bid-tid x10d250/500/875mg>3 monthsBpenicillinβ-lactamase inhibitor
GenericPO
acetazolamide500mg po bid125/250mg500mg ('Sequels')>12 yearsCcarbonic anhydrase inhibitor↓ aqueous production
GenericPO
dicloxacillin250mg po qid250/500mg>3 monthsBpenicillin
GenericPO
famciclovir250mg po tid x 7d (simplex)500mg po tid x 7d (zoster)125/250/500mgNABguanine analogue
GenericPO
cephalexin1-4g/d po250/500/750mg>1 yearBcephalosporin
GenericPO
acetaminophen 300mgcodeine 30mgq4-6hsingle tablet>18 yearsCanalgesicnarcotic (Sch.III)
GenericPO
acetaminophen 325mgtramadol 37.5mgq4-6h(max 8 tabs/d)single tablet>12 yearsCanalgesicnarcotic (Sch.IV)
GenericPO
tramadol hydrochlorideq4-6h(max 400mg/d)50mg>18 yearsCnarcotic (Sch.IV)
GenericPO
valcyclovir500mg po tid (simplex)1g po tid x7d (zoster)500mg/1g>12 yearsBguanine analogue
GenericPO
doxycycline100mg po bid x7d50/100mg>8 yearsDtetracycline
GenericPO
acetaminophen 300mghydrocodone 5mgq4-6h(max 12 tabs/d)single tabletNACnarcotic (Sch.II)
GenericPO
azithromycinbid po x1d, then qd po x4d250mg x6250/500/600mg>6 monthsBmacrolide
GenericPO
acyclovir400mg po 5x/d x7d (simplex)800mg po 5x/d x7d (zoster)200/400/800mg>2 yearsBinhibits DNA polymerase